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Does comorbidity explain the ethnic inequalities
in cervical cancer survival in New Zealand?
A retrospective cohort study
Naomi Brewer1*, Barry Borman1, Diana Sarfati2, Mona Jeffreys3, Steven T Fleming4, Soo Cheng1 and Neil Pearce1,5
Abstract
Background: There are large ethnic differences in cervical cancer survival in New Zealand that are only partly
explained by stage at diagnosis. We investigated the association of comorbidity with cervical cancer survival, and
whether comorbidity accounted for the previously observed ethnic differences in survival.
Methods: The study involved 1,594 cervical cancer cases registered during 1994-2005. Comorbidity was measured
using hospital events data and was classified using the Elixhauser instrument; effects on survival of individual
comorbid conditions from the Elixhauser instrument were also assessed. Cox regression was used to estimate
adjusted cervical cancer mortality hazard ratios (HRs).
Results: Comorbidity during the year before diagnosis was associated with cervical cancer-specific survival: those
with an Elixhauser count of ≥3 (compared with a count of zero) had a HR of 2.17 (1.32-3.56). The HR per unit of
Elixhauser count was 1.25 (1.11-1.40). However, adjustment for the Elixhauser instrument made no difference to the
mortality HRs for Māori and Asian women (compared to ‘Other’ women), and made only a trivial difference to that
for Pacific women. In contrast, concurrent adjustment for 12 individual comorbid conditions from the Elixhauser
instrument reduced the Māori HR from 1.56 (1.19-2.05) to 1.44 (1.09-1.89), i.e. a reduction in the excess risk of 21%;
and reduced the Pacific HR from 1.95 (1.21-3.13) to 1.62 (0.98-2.68), i.e. a reduction in the excess risk of 35%.
Conclusions: Comorbidity is associated with cervical cancer-specific survival in New Zealand, but accounts for only
a moderate proportion of the ethnic differences in survival.
Background
In 2005, cervical cancer was the ninth most common
site of cancer registration for New Zealand females [1],
and the incidence and mortality rates were moderately
high compared with the rest of the developed world [2].
Incidence and mortality rates are not the same across
ethnic groups within New Zealand. For example, in
2005, Māori women had an incidence rate of 9.0, Pacific
women 16.3 and ‘Other’ (predominantly European)
women 5.6 per 100,000 women; Māori women had a
mortality rate of 6.5, Pacific women 7.1 and ‘Other’
women 1.4 per 100,000 women [1].
We have previously reported demographic differences
in cervical cancer survival in New Zealand [3]. Māori
and Pacific women had higher death rates than ‘Other’
women, whereas Asian women had a lower risk. Adjust-
ment for stage at diagnosis, socio-economic position
(SEP), and urban/rural residence explained only some of
the increased risks in Māori and Pacific women. Ethnic
differences in stage at diagnosis were not entirely
explained by differences in screening history [4,5]. There
is some evidence of limited differences in treatment
between Māori and non-Māori women, but these differ-
ences have little impact on survival differences [6].
Thus, the reasons for the differences in survival are cur-
rently unclear, but one possibility not previously exam-
ined is that they may, in part, be due to differences in
comorbidity at the time of cervical cancer diagnosis.
Māori and Pacific women have higher rates of many dis-
eases, including smoking-related respiratory diseases,
diabetes and cardiovascular disease [7-9]. Such comor-
bid conditions may have effects prior to diagnosis (e.g.
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influence the likelihood of cancer screening or late-stage
diagnosis) [10,11], or affect survival post-diagnosis either
directly (e.g. some comorbid conditions may adversely
affect prognosis) or indirectly (e.g. some comorbid con-
ditions may affect or limit treatment options or deci-
sions). In New Zealand, comorbidity has been found to
contribute to ethnic-specific survival disparities for
colon cancer [12], the management of stages I and II
non-small-cell lung cancer [13], and adverse event sta-
tus, inpatient death and increased length of stay in
selected Auckland hospitals [14]. Internationally comor-
bidity has also been found to adversely affect survival in
patients with a range of conditions, including cervical
cancer [15-21].
We therefore investigated the associations of various
comorbid conditions with cervical cancer survival, and
whether these comorbid conditions accounted for the
previously observed ethnic differences in survival.
Methods
The source population comprised all cervical cancer
cases registered with the New Zealand Cancer Registry
(NZCR) between 1 January 1994 and 30 December 2005
[3,4]. The NZCR records self-identified ethnicity, and
allows for multiple responses. Participants who reported
more than one ethnicity were classified into a single eth-
nicity using the standard system of prioritisation: Māori
> Pacific > Asian > ‘Other’ [22]. Participants with miss-
ing ethnicity data were included in the ‘Other’ (predomi-
nantly European) ethnic group in the analyses. This
approach is standard practice in New Zealand health
research [23,24]. All registrations include the National
Health Index (NHI) number which uniquely identifies
individual health care users; this was used to obtain
cause-specific mortality data (from the Mortality Collec-
tion) up to the end of December 2005 (the most recent
year for which data was available), and hospital events
data (from the National Minimum Dataset (NMDS); up
to 99 diagnosis/procedure codes may be provided to the
NMDS) from 1988 to 31 December 2005.
SEP was estimated using the New Zealand Deprivation
Index 2001 (NZDep), an area-based measure derived
from a combination of nine socioeconomic variables
derived from the national census [25]. Each participant
was assigned a score based upon the residential area
(the domicile code) in which they lived, as recorded on
the NZCR at the time of registration. These scores were
then grouped into quintiles [25].
The domicile code recorded for each participant was
also used to assign urban/rural residence according to
population size [26]. Participants were classified as living
in a main urban area (with a population of ≥30,000), a
secondary or minor urban area (population ≥1,000 to
29,999), or a rural area (population <1,000).
Data on stage at diagnosis were obtained from the
NZCR, and reported using the International Federation
of Gynecology and Obstetrics (FIGO) system [27]. In
order to provide sufficient numbers in each category,
the FIGO stages were grouped into four categories:
stages 0 to IB2; II to IIB; III to IIIB; IVA to IVB. A fifth
category of ‘missing’ was utilised for cases where the
FIGO stage was unknown. We conducted a basic sensi-
tivity analysis, to assess the potential for bias resulting
from the exclusion of the women with missing stage
data; this involved three sets of analyses: (i) adjusting for
stage and excluding the women with missing stage data;
(ii) including the women with and without missing stage
data, and adjusting for stage with a dummy variable
representing the women with missing stage data; and
(iii) including the women with and without missing
stage data, but not adjusting for stage. The three sets of
analyses yielded the same patterns. We therefore present
here the findings from the first method (i.e. excluding
women with missing stage), because it is necessary to
adjust for stage, and this is the only approach that
enables us to do this validly [3,4].
We used two widely utilised comorbidity measures.
The Elixhauser instrument [28] was designed specifically
for use with administrative data, and is based on a set of
30 comorbid conditions which were associated with
increased length of stay, hospital charges and mortality
among non-maternal inpatients in California in 1992
[28]. The Charlson Comorbidity Index (CCI) [29] com-
prises 19 comorbid conditions which are given a weight
of 1 to 6 on the basis of the strength of their association
with one-year mortality among a cohort of 607 general
medical patients in the United States [29]. To our
knowledge this is the first study of the role of comorbid-
ity in cervical cancer survival in New Zealand, and there
was therefore no prior data on which of these two (or
any other) comorbidity measures were most appropriate
to use. In general, we found very similar results with the
two comorbidity measures, and we have therefore only
reported the findings for the Elixhauser instrument (the
findings for the CCI are available as Additional file 1
Tables S1-S4); effects on survival of individual comorbid
conditions from the Elixhauser instrument were also
assessed.
Comorbidity was assessed, using the hospital events
data, according to the enhanced ICD-9-CM (for data
from 1988-1999) and ICD-10 (for data from 2000-2005)
coding algorithms of Quan et al [30] for the Elixhauser
instrument [28] and the CCI [29]. We used both the
primary and the secondary diagnoses fields to identify
comorbid conditions during the period one year, and
the period five years, preceding, and including, the date
of diagnosis. The optimal look-back period (the time
over which to identify comorbid conditions) was not
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clear since shorter times may capture more active con-
ditions and longer periods may be more likely to iden-
tify all of the important comorbid conditions [31]. We
therefore utilised two look-back periods, with five years
being the longest timeframe over which we had data for
all of the women. In general, we found similar results
with the two look-back periods (see Additional file 1
Tables S1-S3), though the associations of comorbidity
with survival were somewhat stronger when using the
one-year look-back period; we therefore only report
here the findings for the one-year look-back period. We
included comorbid conditions identified up to and
including the date of diagnosis to strike a balance
between identifying all of the comorbid conditions that
the women had at the time of diagnosis whilst attempt-
ing to avoid including conditions that may have been
caused by treatment after diagnosis. Metastatic solid
tumours were excluded from both comorbidity algo-
rithms, as were all diagnosis codes for cervical cancer.
For each woman, the comorbidity frequency (for the
Elixhauser instrument) and score (for the CCI) were
recorded (for use as continuous variables) and were also
then categorised into (two sets of) four groups (0, 1, 2,
and ≥3).
The Elixhauser measure was calculated using the Sta-
tistical Analysis System (SAS) software 9.1, whilst all
other analyses were conducted using Intercooled Stata
10 for Windows (StataCorp, College Station, Texas,
USA). The Cox proportional hazards model [32] was
used to estimate the hazard ratios (HRs) for cervical
cancer mortality, ‘other mortality’ (non-cervical cancer),
and total mortality associated with the Elixhauser count,
as well as with ethnicity, NZDep, and urban/rural resi-
dence, adjusted for age, registration year, and stage at
diagnosis. Women were censored at the time of their
death or on 31 December 2005 if they were still alive at
that time [3]. In the final set of analyses, the HRs for
each ethnic group were estimated adjusted for the Elix-
hauser count, and, finally, for the individual comorbid
conditions that had a HR of ≥1.5.
The New Zealand Central Ethics Committee granted
ethical approval for the study (CEN/08/04/EXP).
Results
There were 2,323 cases of cervical cancer registered on
the NZCR between 1 January 1994 and 31 December
2005, and all of these cases were included in the
descriptive analyses of comorbidity (Table 1). Using a
one-year look-back period, 15.6% of cases had had at
least one comorbidity (included in the Elixhauser instru-
ment) event in the year before diagnosis; the percen-
tages were similar in Asian (13.3%) and ‘Other’ women
(13.7%), but were highest in Pacific women (32.4%),
with Māori women having an intermediate value
(19.7%). The Elixhauser count was strongly associated
with NZDep, and FIGO stage, but was only weakly asso-
ciated with urban/rural residence and time period of
diagnosis.
For the analyses of the effects of comorbidity on mor-
tality (Table 2), the following exclusions were made; 621
because they did not have a FIGO code (including 17
women whose cancer registration was made on the date
of the their death, and 50 women that could not be
assigned an NZDep score), 77 cases because they did
not have a domicile code that could be assigned an
NZDep score, and a further 31 cases because they were
diagnosed after 30 June 2005 (and therefore had a
potential follow-up time of less than six months),
Table 1 Characteristics of cervical cancer cases, n (%)
Elixhauser co-morbidities
Total 0 1 2 3+
Total 2,323 (100) 1,960 (84.4) 223 (9.6) 63 (2.7) 77 (3.3)
FIGO stage
0 to IB2 1,155 (49.7) 1,067 (92.4) 63 (5.5) 13 (1.1) 12 (1.0)*
II to IIB 262 (11.3) 207 (79.0) 32 (12.2) 11 (4.2) 12 (4.6)
III to IIIB 232 (10.0) 169 (72.8) 41 (17.7) 16 (6.9) 6 (2.6)
IVA to IVB 53 (2.3) 33 (62.3) 11 (20.8) 3 (5.7) 6 (11.3)
Missing 621 (26.7) 484 (77.9) 76 (12.2) 20 (3.2) 41 (6.6)
Ethnicity
Other 1,674 (72.1) 1,444 (86.3) 141 (8.4) 41 (2.5) 48 (2.9)*
Māori 416 (17.9) 334 (80.3) 50 (12.0) 15 (3.6) 17 (4.1)
Pacific 105 (4.5) 71 (67.6) 21 (20.0) 3 (2.9) 10 (9.5)
Asian 128 (5.5) 111 (86.7) 11 (8.6) 4 (3.1) 2 (1.6)
NZDep2001,
quintiles
1 (Least
deprived)
298 (12.8) 277 (93.0) 14 (4.7) 3 (1.0) 4 (1.3)**
2 333 (14.3) 283 (85.0) 33 (9.9) 8 (2.4) 9 (2.7)
3 416 (17.9) 350 (84.1) 37 (8.9) 12 (2.9) 17 (4.1)
4 526 (22.6) 432 (82.1) 56 (10.7) 19 (3.6) 19 (3.6)
5 (Most
deprived)
623 (26.8) 510 (81.9) 67 (10.8) 21 (3.4) 25 (4.0)
Missing 127 (5.5) 108 (85.0) 16 (12.6) 0 3 (2.4)
Urban/rural
residency
Main urban 1,640 (70.6) 1,403 (85.6) 141 (8.6) 42 (2.6) 54 (3.3)NS
Secondary
urban
361 (15.5) 288 (79.8) 47 (13.0) 13 (3.6) 13 (3.6)
Rural 196 (8.4) 162 (82.7) 19 (9.7) 8 (4.1) 7 (3.6)
Missing 126 (5.4) 107 (84.9) 16 (12.7) 0 3 (2.4)
Year of diagnosis
1994-1997 843 (36.3) 714 (84.7) 82 (9.7) 24 (2.9) 23 (2.7)NS
1998-2001 815 (35.1) 689 (84.5) 79 (9.7) 20 (2.5) 27 (3.3)
2002-2005 665 (28.6) 557 (83.8) 62 (9.3) 19 (2.9) 27 (4.1)
p value based on Pearson’s chi-squared
* p = 0.0001
** p = 0.02
NS: Not significant at 95%
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leaving 1,594 women to be included in the analyses. The
women that were excluded because they did not have a
FIGO code had a similar ethnic and SEP distribution to
the cases that did have a FIGO code [4].
Of the 1,594 women included in the analyses: 99.2%
were diagnosed based upon the histology of the primary
malignant tumour [3]; 1,163 (73%) identified as ‘Other’
ethnicity, 312 of whom died during the follow-up per-
iod, 241 (77%) due to cervical cancer, and 71 (23%) due
to other causes; 292 identified as Māori ethnicity (18%),
104 of whom died, 92 (88%) due to cervical cancer, and
12 (12%) due to other causes; 59 (4%) identified as Paci-
fic ethnicity, 20 of whom died, 20 (100%) due to cervical
cancer; and, 80 (5%) identified as Asian ethnicity, 14 of
whom died, 13 (93%) due to cervical cancer, and 1 (7%)
due to other causes.
Table 2 shows the HRs for cervical cancer survival by
comorbidity, adjusted for age, year of diagnosis, stage,
ethnicity, NZDep, and urban/rural residence. Comorbid
disease in the year before diagnosis was associated with
cervical cancer-specific survival: those with an Elixhau-
ser count of 3 or more had a HR of 2.17 (1.32-3.56).
The HR was associated with a per unit increase (when
analysing the Elixhauser instrument as a continuous
variable) of 1.25 (1.11-1.40). Comorbidity was more
strongly associated with mortality from conditions other
than cervical cancer: those with an Elixhauser count of
3 or more had a HR for other mortality of 2.76 (1.04-
7.30). The HR was associated with a per unit increase of
1.46 (1.18-1.79).
We estimated the cervical cancer-specific survival HRs
adjusted for age, year of diagnosis, stage, ethnicity,
NZDep and urban/rural residence, for those with indivi-
dual conditions included in the Elixhauser instrument
(see Additional file 1 Table S3). Thirteen of the individual
comorbid conditions showed HRs of ≥1.5 in the one-year
look-back period; congestive heart failure (2.35 95% CI
1.22-4.52), valvular disease (2.84, 0.70-11.61), compli-
cated hypertension (1.74, 0.24-12.72), chronic pulmonary
disease (1.62, 0.95-2.77), uncomplicated diabetes (2.17,
1.33-3.53), complicated diabetes (10.46, 3.01-36.37), renal
failure (4.27, 2.08-8.76), liver disease (2.43, 0.76-7.78),
coagulopathy (2.78, 0.68-11.43), obesity (3.52, 1.55-7.98),
fluid and electrolyte disorders (4.03, 2.01-8.08), blood
loss anaemia (2.44, 1.48-4.00), and drug abuse (3.28,
0.45-23.76). We therefore adjusted for these individual
comorbid conditions in the final analyses, except for
uncomplicated diabetes because the methodology of the
Elixhauser instrument allows for a woman to be recorded
as having both uncomplicated and complicated diabetes
(where the Elixhauser count was used, only complicated
diabetes (or complicated hypertension) was included
when the woman also had uncomplicated diabetes (or
uncomplicated hypertension)).
Table 3 shows the findings for ethnic differences in
cervical cancer-specific survival adjusted for comorbidity
as a continuous variable and for the 12 individual
comorbid conditions. Adjustment for the Elixhauser
count made no difference to the cervical cancer-specific
survival HRs for Māori and Asian women (compared to
‘Other’ women), and made only a trivial difference to
that for Pacific women. The largest change was for Paci-
fic women, where the HR fell from 1.95 (1.21-3.13) to
1.92 (1.20-3.09). However, the HRs changed more sub-
stantially when adjustment was made for all 12 of the
individual comorbid conditions; the HR for Māori
women fell from 1.56 (1.19-2.05) to 1.44 (1.09-1.89),
representing a 21% decrease in the excess mortality risk;
the HR for Pacific women fell from 1.95 (1.21-3.13) to
1.62 (0.98-2.68), representing a 35% decrease in the
excess mortality risk.
Discussion
This study found that comorbidity is associated with
cervical cancer-specific mortality and more strongly
with mortality from other causes. This latter finding is
not surprising since some cervical cancer patients who
have a comorbidity may die from this comorbidity, and
this group would therefore be expected to have a higher
death rate from “other causes” (i.e. all causes of death
other than cervical cancer) than cervical cancer patients
who do not have a comorbidity.
Adjusting for the Elixhauser instrument produced lit-
tle change in the ethnic differences in mortality. In
Table 2 Mortality by comorbidity
Comorbidity HR (95%CI)a
Cervical cancer
Elixhauser (1 unit) 1.25 (1.11-1.40)
Elixhauser 0 1.00b
Elixhauser 1 1.29 (0.96-1.75)
Elixhauser 2 1.33 (0.83-2.13)
Elixhauser 3+ 2.17 (1.32-3.56)
Other mortality (not cervical cancer)
Elixhauser (1 unit) 1.46 (1.18-1.79)
Elixhauser 0 1.00b
Elixhauser 1 2.49 (1.39-4.44)
Elixhauser 2 2.62 (1.20-5.72)
Elixhauser 3+ 2.76 (1.04-7.30)
Total mortality
Elixhauser (1 unit) 1.28 (1.15-1.41)
Elixhauser 0 1.00b
Elixhauser 1 1.47 (1.13-1.92)
Elixhauser 2 1.48 (0.99-2.21)
Elixhauser 3+ 2.20 (1.41-3.41)
a Adjusted for age, year of diagnosis, stage, ethnicity, socioeconomic position,
and urban/rural residence
b Reference category
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contrast, adjustment for 12 individual comorbid condi-
tions included in the Elixhauser instrument reduced the
excess HR for Māori women by 21% and for Pacific
women by 35%.
A strength of the study is that the Cancer Registry
Act came into effect in 1994 making cancer registra-
tion mandatory [1], and case under-ascertainment unli-
kely [23]. Death registration is also mandatory in New
Zealand, and can be linked to cancer registrations
using the NHI number; thus there is a high probability
that the study identified all of the cases that died in
New Zealand. There may have been some misclassifi-
cation of cause of death, but it is unlikely to have pro-
duced significant bias in the ethnic comparisons [33].
Furthermore, classification of the cause of death for
patients on the NZCR is highly accurate since in cases
that are registered prior to death, information from the
Cancer Registry is used to classify the underlying cause
of death [34].
Other possible limitations of the study include the
potential misclassification of ethnicity, which has been
estimated to produce a 17% undercount of Māori cancer
registrations [35] (this involves misclassification of eth-
nicity on registrations, rather than case under-ascertain-
ment). Thus, the ‘Other’ ethnic group may contain some
Māori cases that were incorrectly classified, thereby
diluting the ethnic survival differences. There is also evi-
dence of a 6-7% undercount of Māori deaths [35,36],
but this would not bias the current study since the
ethnicity recorded on the Cancer Registry was used in
all analyses. The classification of ethnicity was based on
the wording of the corresponding census questions, and
these have changed over time, but once again this is
unlikely to have produced serious bias because the eth-
nicity recorded on the Cancer Registry was also used to
classify the corresponding deaths, and the analyses were
adjusted for year of diagnosis. There may also be mis-
classification of area-based SEP and urban/rural resi-
dence in cancer registrations, but in each instance, any
such misclassification is unlikely to be associated with
subsequent survival and, if anything, is likely to produce
underestimates of the differences in survival between
these various demographic groups.
The greatest change in the ethnic-specific HRs
occurred when adjustment was made for the 12 indivi-
dual comorbid conditions, rather than using the sum-
mary Elixhauser comorbidity measure. Some of these
individual comorbid conditions may have shown ele-
vated HRs by chance, because of the large number of
comparisons involved.
The comorbidity data was based on administrative in-
hospital data and therefore some conditions may not have
been recorded. However, a study on colon cancer in New
Zealand found that despite comorbid conditions being
recorded more frequently in patients’ medical notes than
in administrative data, the use of a comorbidity measure
still improved the prediction of all-cause survival in a mul-
tivariable model [37]. It is also possible that some patients
Table 3 Cervical cancer-specific mortality by ethnicity adjusted for comorbidity
Ethnicity
Comorbidities Comorbidity Other Māori Pacific Asian
HR (95%CI)a HR (95%CI)b HR (95%CI)c HR (95%CI)c HR (95%CI)c
No comorbidity adjustment/inclusion 1.00 1.56 (1.19-2.05) 1.95 (1.21-3.13) 0.72 (0.41-1.27)
Elixhauser as continuous variable 1.25 (1.11-1.40) 1.00 1.55 (1.19-2.04) 1.92 (1.20-3.09) 0.72 (0.41-1.26)
Individual comorbities
Congestive heart failure 2.35 (1.22-4.52) 1.00 1.57 (1.20-2.06) 1.98 (1.23-3.17) 0.72 (0.41-1.27)
Valvular disease 2.84 (0.70-11.61) 1.00 1.56 (1.19-2.04) 1.96 (1.22-3.14) 0.72 (0.41-1.27)
Hypertension, complicated 1.74 (0.24-12.72) 1.00 1.57 (1.19-2.06) 1.95 (1.22-3.13) 0.72 (0.41-1.27)
Chronic pulmonary disease 1.62 (0.95-2.77) 1.00 1.55 (1.18-2.03) 1.95 (1.22-3.13) 0.67 (0.38-1.19)
Diabetes, complicated 10.46 (3.01-36.37) 1.00 1.55 (1.18-2.04) 1.70 (1.03-2.80) 0.71 (0.40-1.25)
Renal failure 4.27 (2.08-8.76) 1.00 1.58 (1.20-2.07) 1.70 (1.04-2.77) 0.72 (0.41-1.27)
Liver disease 2.43 (0.76-7.78) 1.00 1.55 (1.18-2.03) 1.92 (1.20-3.09) 0.72 (0.41-1.26)
Coagulopathy 2.78 (0.68-11.43) 1.00 1.55 (1.18-2.03) 1.91 (1.19-3.07) 0.72 (0.41-1.27)
Obesity 3.52 (1.55-7.98) 1.00 1.55 (1.18-2.04) 1.90 (1.18-3.05) 0.72 (0.41-1.27)
Fluid and electrolyte disorders 4.03 (2.01-8.08) 1.00 1.51 (1.15-1.98) 1.97 (1.23-3.16) 0.69 (0.39-1.21)
Blood loss anaemia 2.44 (1.48-4.00) 1.00 1.53 (1.17-2.01) 1.98 (1.23-3.17) 0.71 (0.40-1.26)
Drug abuse 3.28 (0.45-23.76) 1.00 1.56 (1.19-2.04) 1.95 (1.22-3.13) 0.72 (0.41-1.27)
Multivariate - all 12 of the above 1.00 1.44 (1.09-1.89) 1.62 (0.98-2.68) 0.63 (0.35-1.13)
a Adjusted for age, year of diagnosis, stage, ethnicity, socioeconomic position, and urban/rural residence
b Reference category
c Adjusted for age, year of diagnosis, stage, ethnicity, socioeconomic position, urban/rural residence, and comorbidity index
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had undiagnosed disease, but misclassification of this type
would probably decrease the effect of comorbidity on sur-
vival [37].
To date, there have been few studies of the role of
comorbid conditions in cervical cancer survival, and
none in New Zealand. Our results are generally consis-
tent with those of Coker et al. [15] who found that in
Texan women aged 65 years or older with cervical
cancer, those that had one or more comorbid condi-
tions were 40% more likely to die (from all causes)
compared with women who did not have any comor-
bid conditions. However, unlike Coker et al. [15] who
did not find an independent association between
comorbidity and cervical cancer-specific survival, we
found an independent 25% increased risk of death
from cervical cancer for each unit increase of the Elix-
hauser count (Table 3). In a study of stage IB squa-
mous cell carcinoma, Hopkins and Morley [17] found
that women with diabetes had an 82% cumulative 5-
year all-cause survival compared with an 89% survival
in those who did not have diabetes (p = 0.04). These
findings are also consistent with the 10-fold increased
risk of cervical cancer-specific mortality in the present
study. In contrast to our study, Leath et al. [38] did
not find comorbid conditions to be an independent
predictor of survival in women with either early or late
stage cervical cancer.
The present study has shown that Māori and Pacific
women have a larger number of comorbid conditions
than ‘Other’ and Asian women when measured with the
Elixhauser instrument with a one-year look-back period
(Table 1). Women living in more deprived areas had lar-
ger numbers of comorbid conditions according to the
Elixhauser instrument. We found independent associa-
tions between the Elixhauser count and cervical cancer-
specific, ‘other’ and total mortality (Table 2).
Reducing ethnic inequalities in cancer is one of the over-
all purposes of the New Zealand Cancer Control Strategy
[39]. We and others [1,3,40,41] have previously demon-
strated substantial ethnic inequalities in cervical cancer
incidence, mortality and survival in New Zealand. It has
been suggested [42] that comorbid conditions, which are
known to differ between ethnic groups [7], could account
for these inequalities and, as mentioned earlier, there is
some international evidence of comorbidity adversely
affecting cervical cancer survival [15,17,18]. The current
study, the first to empirically investigate this issue in New
Zealand, only partially supports this hypothesis. It is possi-
ble that there are small ethnic differences at each stage of
the cancer continuum (screening, diagnosis, treatment,
comorbidity, follow-up, etc) and that each of these makes
a small contribution to the major overall ethnic differences
in survival that we have reported.
Conclusion
In summary, we assessed the roles of comorbid condi-
tions identified through hospital events data and found
that these conditions are associated with cervical can-
cer-specific mortality, but account for only a moderate
proportion of the ethnic differences in survival. Other
factors, including possible differences in treatment and
follow-up, may also play a role.
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